Griffin Asset Management Inc. lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.7% in the third quarter, Holdings Channel reports. The institutional investor owned 125,600 shares of the healthcare product maker’s stock after selling 2,135 shares during the quarter. Abbott Laboratories makes up 1.4% of Griffin Asset Management Inc.’s portfolio, making the stock its 14th largest holding. Griffin Asset Management Inc.’s holdings in Abbott Laboratories were worth $9,214,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the stock. Signature Estate & Investment Advisors LLC acquired a new position in Abbott Laboratories during the 3rd quarter valued at about $103,000. Atlantic Trust LLC acquired a new position in Abbott Laboratories during the 2nd quarter valued at about $104,000. Fort L.P. acquired a new position in Abbott Laboratories during the 2nd quarter valued at about $119,000. Security National Bank of SO Dak boosted its stake in Abbott Laboratories by 72.0% during the 2nd quarter. Security National Bank of SO Dak now owns 2,098 shares of the healthcare product maker’s stock valued at $128,000 after purchasing an additional 878 shares during the period. Finally, Mainstay Capital Management LLC ADV boosted its stake in Abbott Laboratories by 1,069.5% during the 2nd quarter. Mainstay Capital Management LLC ADV now owns 4,374 shares of the healthcare product maker’s stock valued at $131,000 after purchasing an additional 4,000 shares during the period. 72.82% of the stock is owned by institutional investors and hedge funds.
A number of research firms have issued reports on ABT. Credit Suisse Group began coverage on shares of Abbott Laboratories in a research note on Monday. They set an “outperform” rating and a $82.00 target price for the company. BTIG Research reissued a “hold” rating on shares of Abbott Laboratories in a research note on Thursday, October 18th. Goldman Sachs Group raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and set a $74.10 target price for the company in a research note on Sunday, December 9th. Raymond James boosted their target price on shares of Abbott Laboratories from $72.00 to $77.00 and gave the company an “outperform” rating in a research note on Monday, September 24th. Finally, UBS Group began coverage on shares of Abbott Laboratories in a research note on Tuesday, November 27th. They set a “buy” rating and a $83.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $75.96.
Shares of NYSE:ABT opened at $70.08 on Wednesday. The company has a market capitalization of $122.50 billion, a PE ratio of 28.03, a P/E/G ratio of 2.07 and a beta of 1.40. Abbott Laboratories has a twelve month low of $55.58 and a twelve month high of $74.92. The company has a quick ratio of 1.13, a current ratio of 1.42 and a debt-to-equity ratio of 0.62.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 17th. The healthcare product maker reported $0.75 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.75. The company had revenue of $7.66 billion during the quarter, compared to analyst estimates of $7.65 billion. Abbott Laboratories had a net margin of 2.91% and a return on equity of 16.05%. The business’s revenue for the quarter was up 12.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.66 EPS. Equities analysts forecast that Abbott Laboratories will post 2.89 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, February 15th. Stockholders of record on Tuesday, January 15th will be paid a $0.32 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.28. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date of this dividend is Monday, January 14th. Abbott Laboratories’s dividend payout ratio is currently 44.80%.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://weekherald.com/2018/12/19/griffin-asset-management-inc-sells-2135-shares-of-abbott-laboratories-abt.html.
Abbott Laboratories Company Profile
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other.
Featured Story: Why do company’s buyback their stock?
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.